Profund Advisors LLC Raises Holdings in Immunovant, Inc. $IMVT

Profund Advisors LLC lifted its position in shares of Immunovant, Inc. (NASDAQ:IMVT) by 120.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 49,076 shares of the company’s stock after acquiring an additional 26,810 shares during the quarter. Profund Advisors LLC’s holdings in Immunovant were worth $1,248,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in IMVT. Geneos Wealth Management Inc. purchased a new stake in Immunovant during the fourth quarter valued at about $25,000. Strs Ohio purchased a new position in shares of Immunovant in the first quarter worth about $27,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Immunovant in the third quarter valued at approximately $33,000. PNC Financial Services Group Inc. raised its position in shares of Immunovant by 138.9% in the third quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock valued at $46,000 after purchasing an additional 1,646 shares during the period. Finally, FNY Investment Advisers LLC lifted its stake in shares of Immunovant by 100.0% during the 4th quarter. FNY Investment Advisers LLC now owns 4,000 shares of the company’s stock valued at $101,000 after buying an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Analyst Ratings Changes

IMVT has been the subject of a number of recent research reports. Sanford C. Bernstein started coverage on shares of Immunovant in a research note on Friday, March 20th. They issued a “market perform” rating and a $28.00 price objective for the company. The Goldman Sachs Group increased their target price on Immunovant from $29.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a report on Wednesday, April 8th. Guggenheim lifted their price target on Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Immunovant in a research note on Tuesday, February 10th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $32.44.

Immunovant Trading Up 35.3%

Shares of NASDAQ:IMVT opened at $35.56 on Thursday. The company has a 50 day moving average of $26.48 and a 200 day moving average of $25.78. The stock has a market cap of $7.24 billion, a P/E ratio of -13.22 and a beta of 0.70. Immunovant, Inc. has a 12 month low of $13.79 and a 12 month high of $36.29.

Immunovant (NASDAQ:IMVT) last posted its earnings results on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same period last year, the firm posted ($0.64) EPS. On average, equities analysts forecast that Immunovant, Inc. will post -2.67 earnings per share for the current fiscal year.

Key Immunovant News

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Immunovant reported promising Week 16 data from its difficult-to-treat rheumatoid arthritis study, with strong response rates that investors are viewing as evidence the lead program could have meaningful clinical potential. QuiverQuant article
• Positive Sentiment: The company said its cutaneous lupus proof-of-concept study is fully enrolled, with topline results expected in the second half of 2026, keeping multiple catalysts ahead for IMVT-1402. GlobeNewswire article
• Neutral Sentiment: Immunovant reported quarterly results showing a wider-than-expected loss, with EPS of -$0.73 versus the -$0.60 consensus, but the earnings miss appears to have taken a back seat to the clinical update. Earnings report
• Neutral Sentiment: Management also highlighted a strong cash position of about $902 million at March 31, 2026, suggesting enough runway to support development plans through a potential commercial launch. GlobeNewswire article
• Negative Sentiment: Despite the stock’s rally, the company still faces execution risk because IMVT-1402 remains in clinical development and future results will need to confirm today’s optimistic early readout.

Insider Transactions at Immunovant

In related news, Director Atul Pande sold 6,000 shares of the stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $32.00, for a total value of $192,000.00. Following the sale, the director owned 116,731 shares in the company, valued at approximately $3,735,392. This trade represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Tiago Girao sold 25,760 shares of Immunovant stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $29.62, for a total value of $763,011.20. Following the sale, the chief financial officer directly owned 247,596 shares of the company’s stock, valued at $7,333,793.52. This represents a 9.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 78,141 shares of company stock valued at $2,115,713. Corporate insiders own 1.80% of the company’s stock.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.